demand
nonhuman
primat
undoubtedli
increas
meet
biomed
need
current
age
biodefens
avail
fund
increas
research
select
agent
creat
requir
valid
result
relev
primat
model
review
provid
descript
current
potenti
biolog
threat
like
requir
nonhuman
primat
develop
vaccin
therapeut
primat
invalu
resourc
dissect
viral
diseas
pathogenesi
well
test
vaccin
efficaci
dna
vaccin
approach
studi
success
ebola
lassa
anthrax
nonhuman
primat
model
nonhuman
primat
research
monkeypox
provid
insight
role
cytokin
limit
diseas
sever
biodefens
research
focus
select
agent
bacteri
origin
also
benefit
nonhuman
primat
studi
rhesu
macaqu
tradit
model
choic
anthrax
research
yield
success
find
vaccin
develop
plagu
research
african
green
monkey
contribut
vaccin
develop
howev
disadvantag
current
vaccin
undoubtedli
requir
gener
new
vaccin
thu
increas
need
nonhuman
primat
research
unfortun
current
biosafeti
level
bsl
facil
equip
perform
research
limit
may
ultim
imped
progress
era
biodefens
n
increas
demand
nonhuman
primat
undoubtedli
character
new
era
bioterror
becom
realiti
us
food
drug
administr
fda
establish
new
guidelin
test
vaccin
therapeut
select
agentsthos
pathogen
govern
determin
potenti
biolog
weapon
actual
risk
infect
via
bioterrorist
attack
known
natur
occur
infect
quit
rare
neither
ethic
practic
perform
usual
phase
trial
abil
determin
efficaci
would
prohibit
expens
bioterror
agent
occur
rare
natur
abil
determin
efficaci
would
take
year
reason
fda
rule
stockpil
vaccin
therapeut
gener
treatment
determin
effect
two
differ
anim
model
certainli
least
one
anim
model
nonhuman
primat
descript
select
agent
emerg
pathogen
like
requir
use
nonhuman
primat
filovirus
neg
sens
singleseg
rna
virus
well
known
filovirus
ebola
viru
ebov
ebola
first
discov
central
africa
name
river
democrat
republ
congo
formerli
zair
outbreak
began
infect
individu
cotton
factori
spread
rel
index
case
feldmann
et
al
ultim
total
number
infect
individu
death
pattyn
second
epidem
develop
year
case
fatal
rate
ebov
emerg
unit
state
viru
detect
cynomolgu
monkey
macaca
fasciculari
import
philippin
primat
facil
reston
virginia
jahrl
et
al
viru
appear
spread
larg
droplet
andor
smallparticl
aerosol
date
rout
transmiss
remain
uniqu
featur
associ
strain
ebola
known
ebolareston
viru
associ
human
diseas
although
classifi
biosafeti
level
bsl
agent
sinc
origin
descript
ebov
viru
reemerg
sever
time
central
africa
becam
real
threat
public
health
reemerg
kikwit
democrat
republ
congo
current
outbreak
congo
affect
mani
great
ape
walsh
et
al
ebov
rel
marburg
viru
marv
activ
use
weapon
develop
program
pose
potenti
bioterror
threat
alibek
handelman
nonhuman
primat
prefer
anim
model
studi
human
filoviru
infect
anim
fatal
infect
ebov
marv
numer
speci
use
includ
baboon
african
green
monkey
rhesu
cynomolgu
macaqu
patholog
similar
infect
observ
human
difficult
conduct
vaccin
clinic
trial
human
ebov
vaccin
sporad
natur
outbreak
potenti
ethic
difficulti
obtain
approv
rel
rare
appear
ebov
favor
normal
develop
commerci
viabl
vaccin
howev
view
chang
newer
exist
threat
bioterror
vaccin
becam
avail
would
like
given
medic
personnel
first
respond
similar
identifi
risk
smallpox
attack
becom
clear
rodent
model
necessarili
predict
efficaci
antivir
therapeut
gold
standard
remain
nonhuman
primat
trial
feldmann
et
al
jahrl
et
al
fact
vaccin
efficaci
studi
nonhuman
primat
demonstr
vaccin
strategi
success
rodent
abl
protect
primat
form
unit
challeng
viru
geisbert
et
al
arenavirus
biseg
singlestrand
rna
virus
segment
ambisens
contain
two
converg
arrang
gene
separ
intergen
hairpin
loop
among
sever
hemorrhag
fever
caus
arenavirus
lassa
arenaviru
lav
argentinian
hemorrhag
fever
junin
viru
bolivian
hemorrhag
fever
machupo
viru
venezuelan
hemorrhag
fever
guanarito
viru
sabia
viru
lymphocyt
choriomening
viru
prototyp
famili
lav
one
highli
pathogen
arenavirus
name
town
lassa
west
africa
natur
reservoir
viru
rodent
speci
mastomi
natalensi
lav
infect
hundr
thousand
peopl
year
west
africa
yearli
death
toll
total
approxim
mccormick
symptom
infect
includ
fever
edema
hemorrhag
fatal
case
cummin
et
al
area
sierra
leon
diseas
account
medic
inhospit
death
deaf
spontan
abort
transmiss
rodent
human
believ
inhal
nosocomi
spread
lav
also
take
place
hospit
monkey
immun
less
virul
relat
viru
lassa
mopeia
protect
fisherhoch
et
al
lassa
infect
howev
current
approv
vaccin
lassa
junin
viru
identifi
sever
rodent
speci
includ
calomi
musculinu
north
central
argentina
seroposit
human
incub
period
wk
nonspecif
symptom
appear
follow
wk
later
serv
cardiovascular
renal
neurolog
involv
live
attenu
junin
viru
vaccin
proven
safe
effect
guinea
pig
nonhuman
primat
trial
mckee
et
al
mckee
et
al
clinic
trial
human
male
shown
efficaci
maiztegui
et
al
reservoir
machupo
viru
calomi
callosu
rhesu
monkey
african
green
monkey
demonstr
clinic
sign
consist
human
diseas
mcleod
et
al
mcleod
et
al
wagner
et
al
guanarito
viru
carri
zygodontomi
brevicauda
fulhorst
et
al
fulhorst
et
al
sabia
isol
brazil
fatal
human
case
nonhuman
primat
model
guanarito
sabia
describ
date
whitton
bunyavirus
triseg
neg
sens
rna
virus
hantavirus
caus
agent
hemorrhag
fever
renal
syndrom
eurasia
recent
novel
hantaviru
sin
nombr
viru
identifi
caus
hantaviru
pulmonari
syndrom
potenti
lethal
condit
first
identifi
southwestern
unit
state
hantavirus
found
widespread
thoughout
north
south
america
snell
and
viru
first
known
hantaviru
show
humantohuman
spread
hantavirus
rodent
born
vitek
et
al
and
viru
well
studi
probabl
agent
use
biolog
weapon
unknown
recent
nonhuman
primat
use
attempt
understand
pathogenesi
viru
mechan
protect
mcelroy
et
al
demonstr
cynomolog
macaqu
although
manifest
clinic
diseas
manifest
lymphocyt
decreas
infect
mcelroy
et
al
addit
determin
antibodi
gener
rhesu
macaqu
and
protect
syrian
hamster
lethal
challeng
provid
insight
potenti
postexposur
treatment
custer
et
al
crimeancongo
hemorrhag
fever
first
observ
crimea
use
human
volunt
determin
agent
filter
diseas
human
associ
tick
bite
congo
viru
first
isol
africa
blood
sampl
patient
case
five
identifi
laboratori
infect
viru
later
classifi
nairoviru
bunyavirida
famili
transmit
nosocomi
potenti
bioterrorist
threat
due
lack
vaccin
therapeut
agent
gear
et
al
rift
valley
fever
first
identifi
egypt
rang
continu
expand
recent
outbreak
record
arabian
peninsula
cdc
rhesu
macaqu
human
develop
viremia
liver
damag
elev
liver
enzym
rhesu
monkey
human
suffer
seriou
diseas
hemorrhag
phenomena
morril
peter
paramyxovirus
singlestrand
neg
sens
rna
virus
nipah
viru
first
isol
viru
cross
speci
barrier
bat
pig
viru
caus
enceph
infect
human
mortal
lam
chua
current
prophylaxi
vaccin
exist
nipah
howev
antivir
ribavirin
use
empir
therapi
infect
patient
report
effect
although
yet
fulli
evalu
anim
experi
chong
et
al
hamster
anim
model
anim
die
acut
enceph
follow
nipah
viru
infect
guillaum
et
al
wong
et
al
model
shown
passiv
transfer
antibodi
immun
anim
protect
lethal
nipah
viru
challeng
human
relaps
lateonset
case
infect
observ
tan
et
al
wong
et
al
situat
describ
immunobiolog
infect
unknown
none
late
patholog
observ
hamster
model
guillaum
et
al
bangladesh
current
outbreak
nipah
h
feldmann
canadian
center
human
anim
health
winnipeg
manitoba
person
commun
shown
nosocomi
transmiss
nipah
potenti
agent
bioterror
base
sever
characterist
produc
larg
quantiti
cell
cultur
import
criterion
weapon
potenti
aerosol
infect
lam
chua
outbreak
caus
widespread
panic
fear
high
mortal
highli
virul
viru
spread
easili
among
pig
easili
transmit
human
consider
social
disrupt
tremend
econom
loss
import
pigrear
industri
addit
caus
acut
infect
caus
clinic
relaps
month
year
infect
sever
acut
respiratori
syndrom
sar
emerg
sar
world
good
model
effect
outbreak
unknown
viru
global
health
intern
travel
economi
one
region
sar
outbreak
result
case
involv
death
fear
diseas
great
mani
commun
especi
among
healthcar
worker
billion
dollar
lost
airlin
tourism
industri
result
bankruptci
airlin
busi
lingappa
et
al
although
current
list
select
agent
recent
case
laboratoryacquir
sar
may
convinc
us
govern
certainli
potenti
biolog
weapon
mortal
rate
abil
surviv
surfac
long
lipidenvelop
virus
becom
inact
make
good
candid
becom
select
agent
near
futur
current
total
candid
vaccin
develop
sar
requir
valid
nonhuman
primat
initi
report
sar
infect
cynomolgu
macaqu
prove
controversi
anim
model
demonstr
variabl
clinic
featur
best
current
model
appear
address
viral
replic
absenc
clinic
reproduc
bisht
et
al
fouchier
et
al
martina
et
al
first
human
moneypox
case
unit
state
report
may
june
cdc
b
reed
et
al
individu
believ
acquir
infect
prairi
dog
cynomi
spp
becam
ill
contact
variou
exot
african
rodent
ship
ghana
unit
state
monkeypox
health
concern
human
popul
equatori
africa
arita
et
al
jezek
et
al
jezek
et
al
research
natur
biolog
monkeypox
limit
diseas
rare
human
descript
natur
acquir
anim
infect
exist
guarner
et
al
nonhuman
primat
research
provid
valuabl
insight
role
interferon
limit
diseas
sever
cosgriff
et
al
morril
et
al
morril
et
al
understand
pathogenesi
diseas
well
determin
efficaci
vaccin
would
benefit
expand
nonhuman
primat
research
flavivirus
posit
sens
singlestrand
rna
virus
although
select
agent
bioterror
threat
dengu
viru
endem
much
south
america
asia
vaccin
therapi
vie
nonhuman
primat
resourc
although
studi
perform
intens
yr
develop
vaccin
still
commerci
vaccin
avail
dengu
diseas
lack
suitabl
anim
diseas
model
detriment
develop
tetraval
live
attenu
dengu
vaccin
saluzzo
two
candid
live
attenu
dengu
vaccin
current
exist
chimer
dna
vaccin
also
variou
stage
develop
west
nile
viru
emerg
eastern
north
america
major
concern
even
modern
arbovirolog
diseas
potenti
also
alert
world
pathogen
may
turn
anywher
time
west
nile
viru
known
caus
viremia
human
blood
transfus
potenti
risk
first
case
transfus
transmiss
document
komar
number
candid
vaccin
variou
stage
develop
similar
dengu
virus
eventu
requir
access
nonhuman
primat
resourc
b
anthraci
agent
anthrax
gramposit
bacteri
pathogen
infect
human
anim
natur
human
infect
occur
individu
handl
materi
infect
anim
inhal
spore
associ
anim
product
hanna
infect
occur
three
form
cutan
inhal
gastrointestin
left
untreat
form
diseas
result
death
meselson
et
al
fatal
form
diseas
inhal
anthrax
present
sore
throat
mild
fever
muscl
ach
malais
mortal
rate
approxim
even
care
includ
use
antibiot
inglesbi
et
al
recent
use
agent
biolog
weapon
increas
import
research
focus
postexposur
treatment
inglesbi
et
al
inglesbi
et
al
rapid
onset
death
inhal
anthrax
due
septicemia
toxemia
dixon
et
al
bacterium
secret
three
protein
edema
factor
lethal
factor
protect
antigen
pa
elliott
et
al
miller
et
al
mourez
et
al
wesch
et
al
lethal
toxin
edema
toxin
exert
effect
bind
receptorbind
compon
pa
ab
type
toxin
pezard
et
al
fact
vaccin
strategi
target
pa
immun
respons
prevent
coupl
effector
toxin
receptorbind
compon
welko
et
al
pa
also
focu
therapeut
recombin
antibodi
may
eventu
use
treat
case
latestag
anthrax
intox
maynard
et
al
histor
nonhuman
primat
model
inhal
anthrax
rhesu
macaqu
friedland
et
al
fritz
et
al
gleiser
et
al
ivin
et
al
lincoln
et
al
howev
increas
difficulti
obtain
anim
research
led
need
develop
anoth
model
suffici
mimic
human
infect
attempt
made
establish
rabbit
model
small
anim
inhal
anthrax
welko
et
al
zaucha
et
al
nonhuman
primat
model
continu
need
vaccin
efficaci
test
therapeut
test
instanc
survey
efficaci
anthrax
vaccin
adsorb
anthrax
vaccin
among
guinea
pig
rabbit
rhesu
macaqu
result
variabl
protect
challeng
b
anthraci
divers
geograph
origin
recent
studi
shown
cynomologu
macaqu
exhibit
patholog
similar
seen
human
rhesu
monkey
vasconcelo
et
al
gramneg
coccobacillu
f
tularensi
caus
agent
tularemia
former
soviet
union
wide
report
develop
f
tularensi
weaponri
alibek
handelman
organ
first
isol
tular
counti
california
outbreak
plaguelik
diseas
elli
et
al
natur
reservoir
includ
small
mammal
ground
squirrel
hare
vole
muskrat
water
rat
rabbit
rodent
grunow
et
al
agent
spread
human
infect
reservoir
small
vertebr
direct
contact
transmiss
arthropod
vector
tularemia
manifest
variou
way
includ
ulcer
site
inocul
pharyng
lymphadenopathi
pneumonia
elli
et
al
immedi
treatment
appropri
antibiot
reduc
possibl
lifethreaten
pneumonia
live
attenu
vaccin
initi
develop
former
soviet
union
sjostedt
et
al
subsequ
transfer
unit
state
research
identifi
two
variant
blue
gray
coloni
type
soviet
vaccin
strain
immun
guinea
pig
blue
variant
result
increas
resist
lethal
challeng
eigelsbach
down
ultim
current
live
vaccin
strain
lv
deriv
variant
efficaci
test
human
volunt
saslaw
et
al
basi
lv
attenu
determin
well
lack
data
regard
character
immun
respons
vaccin
current
avail
unit
state
futur
vaccin
develop
would
benefit
establish
nonhuman
primat
model
initi
phase
f
tularensi
infect
transient
bacteremia
occur
dissemin
pathogen
throughout
host
within
reticuloendotheli
tissu
presenc
capsul
aid
establish
earli
bacteremia
shield
organ
complementmedi
lysi
sandstrom
et
al
addit
phase
variat
appear
play
role
sustain
viabil
organ
within
macrophag
variat
lp
specif
antigen
lipid
reduc
nitric
oxid
product
permit
bacteri
growth
within
macrophag
cowley
et
al
final
known
virul
determin
abc
transport
encod
vala
gene
essenti
macrophag
growth
cowley
et
al
despit
identif
sever
virul
factor
littl
known
overal
pathogen
genet
makeup
f
tularensi
anim
model
restrict
almost
exclus
murin
model
chen
et
al
eigelsbach
et
al
golovliov
et
al
kudelina
olsufiev
resourc
success
dissect
earli
cytokin
respons
tularemia
nevertheless
nonhuman
primat
model
may
need
investig
pathogenesi
alibek
handelman
pesti
gramneg
bacillu
caus
diseas
histor
refer
plagu
primarili
zoonot
diseas
transmit
bite
infect
flea
less
commonli
handl
consumpt
infect
anim
tissu
brubak
agent
caus
sever
form
diseas
name
bubon
septicem
pneumon
plagu
bubon
plagu
character
swollen
tender
lymph
gland
fever
headach
chill
occur
bacteria
transmit
arthropod
vector
pesti
contamin
materi
enter
bodi
break
skin
hull
et
al
von
reyn
et
al
septicem
plagu
result
bacteria
multipli
blood
may
complic
bubon
pneumon
plagu
hull
et
al
addit
symptom
seen
bubon
plagu
septicem
patient
also
present
abdomin
pain
shock
hemorrhag
skin
intern
organ
hull
et
al
final
pneumon
plagu
contagi
form
diseas
spread
aerosol
bacteria
doll
et
al
meyer
character
rapidli
develop
pneumonia
short
breath
cough
chest
pain
infect
individu
must
treat
within
hr
prevent
fatal
outcom
highli
pathogen
natur
pesti
result
multipl
virul
factor
major
factor
prevent
uptak
bacteria
immun
scaveng
cell
capsular
antigen
corn
et
al
parkhil
et
al
pesti
cell
wall
compon
v
w
antigen
lipoprotein
complex
play
role
prevent
phagocytosi
serum
resist
observ
plagu
infect
result
short
polysaccharid
pesti
prevent
attach
complement
termin
attack
complex
persson
et
al
addit
murin
toxin
shown
induc
shock
respiratori
distress
mice
reminisc
human
diseas
monti
two
vaccin
current
avail
one
vaccin
attenu
strain
pesti
kill
vaccin
origin
develop
unit
state
earli
meyer
william
et
al
vaccin
usual
given
risk
encount
highli
pathogen
strain
militari
troop
research
despit
avail
vaccin
interest
develop
improv
vaccin
major
disadvantag
current
vaccin
previous
spars
number
studi
use
african
green
monkey
vervet
vaccin
pathogenesi
studi
plagu
chen
et
al
chen
et
al
davi
et
al
new
vaccin
candid
identifi
need
nonhuman
primat
model
certainli
increas
nonhuman
primat
remain
best
predictor
success
vaccin
therapi
human
gener
agreement
nation
primat
center
could
undertak
signific
new
research
endeavor
area
includ
biodefens
without
signific
expans
invest
current
work
capac
develop
smaller
nonhuman
primat
could
one
way
enhanc
resourc
nevertheless
nonhuman
primat
resourc
must
expand
fund
satisfi
research
need
biodefens
need
nonhuman
primat
expect
grow
enorm
vaccin
therapi
biolog
weapon
emerg
diseas
develop
smaller
primat
marmoset
may
becom
import
studi
space
limit
primat
facil
unfortun
although
amount
fund
biodefenserel
research
provid
region
center
excel
fund
sourc
nation
institut
allergi
infecti
diseas
exponenti
increas
interest
select
agent
research
small
fraction
provid
primat
resourc
inadequ
deal
vaccin
therapi
develop
yet
develop
nonhuman
primat
model
continu
critic
ensur
true
util
infecti
diseas
research
valu
popul
risk
bioterror
infecti
diseas
